Last updated on August 2018

Safety Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF) CLL DLBCL or ATLL


Brief description of study

Objectives of this clinical trial are to evaluate the safety, tolerability, pharmacokinetics and potential efficacy of the investigational drug, MRG-106, in patients diagnosed with certain lymphomas and leukemias, including cutaneous T-cell lymphoma (CTCL) [mycosis fungoides (MF) subtype], chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and adult T-cell leukemia/lymphoma (ATLL). MRG-106 is an inhibitor of a molecule called miR-155 that is found at high levels in these types of cancers and may be important in promoting the growth and survival of the cancer cells. Participants in the clinical trial will receive weekly doses of MRG-106 administered by injection under the skin or into a vein, or by injection directly into cancerous lesions in the skin (for CTCL only). Blood samples will be collected to measure how MRG-106 is processed by the body, and other measurements will be performed to study how normal and cancerous cells of the immune system respond when exposed to MRG-106.

Detailed Study Description

Study Design:

  • Part A: Cohorts of 3-6 patients diagnosed with MF will receive up to five intratumoral injections of MRG-106 over a period of up to 15 days with follow-up for an additional 20 days, beginning with the maximum deliverable intratumoral dose. Doses may be decreased in subsequent cohorts to determine the minimum pharmacodynamically active dose.
  • Parts B-F: Patients in these parts of the study will be diagnosed with MF (Parts B and C), CLL (Part D), DLBCL (Part E), or ATLL (Part F). All patients will receive subcutaneous or intravenous MRG-106 (or a combination of systemic and intratumoral administration for MF patients only) on Days 1, 3 and 5, and will continue dosing on a weekly schedule until the patient becomes intolerant, develops clinically significant side effects, progresses, or the trial is terminated. Doses administered will not exceed a dose level predicted to be safe based on all prior treatment experience with the drug. Patients in Part B may continue on a stable background therapy for their disease during their treatment with MRG-106, while patients in Parts C-F will be treated with MRG-106 alone.

Clinical Study Identifier: NCT02580552

Contact Investigators or Research Sites near you

Start Over

Christiane Querfeld, MD

City of Hope
Duarte, CA United States
  Connect »

Herbert Eradat, MD

UCLA Department of Medicine
Los Angeles, CA United States
  Connect »

Lauren Pinter-Brown, MD

Chao Family Comprehensive Cancer Center at University of California, Irvine
Orange, CA United States
  Connect »

miRagen Therapeutics, Inc.

Stanford University Hospital and Clinics
Stanford, CA United States
  Connect »

miRagen Therapeutics, Inc.

University of Colorado, Anschutz Medical Campus
Aurora, CO United States
  Connect »

Francine Foss, MD

Smilow Cancer Hospital at Yale-New Haven
New Haven, CT United States
  Connect »

miRagen Therapeutics, Inc.

Northwestern University; Department of Dermatology
Chicago, IL United States
  Connect »

Basem William, MD

The Ohio State University Comprehensive Cancer Center
Columbus, OH United States
  Connect »

William Wierda, MD

The University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »

Ahmad Halwani, MD

Huntsman Cancer Institute
Salt Lake City, UT United States
  Connect »

Jennifer DeSimone, MD

Inova Melanoma and Skin Cancer Center / Inova Schar Cancer Institute
Fairfax, VA United States
  Connect »

Thomas Kipps, MD, PhD

UCSD Moores Cancer Center
La Jolla, CA United States
  Connect »

Alison Moskowitz, MD

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »

Pierluigi Porcu, MD

Thomas Jefferson University Hospital
Philadelphia, PA United States
  Connect »

Juan Carlos Ramos, MD

University of Miami Sylvester Comprehensive Cancer Center
Miami, FL United States
  Connect »

Robin Joyce, MD

Beth Israel Deaconess Medical Center
Boston, MA United States
  Connect »

Matthew A. Lunning, DO

University of Nebraska Medical Center
Omaha, NE United States
  Connect »

Murali Janakiram, MD

Montefiore Medical Center, Albert Einstein College of Medicine
Bronx, NY United States
  Connect »

Adrienne A. Phillips, MD

Weill Cornell Medicine
New York, NY United States
  Connect »